Rahway, NJ, and New York, May 29, 2024 (Business Wire) -- Merck is acquiring EyeBio, a biotech company focused on eye diseases, in a deal potentially worth $3 billion. This move strengthens Merck's ophthalmology presence and bolsters its pipeline with promising candidates, including a late-stage drug for macular degeneration expected to enter a pivotal trial later this year.
Read full article here.
San Diego, CA, July 11, 2024 (PRNewswire) -- Element Biosciences has raised over $277 million in Series D funding, bringing its total funding to over $680 million. The round was led by Wellington Ma
Corte Madera, CA, July 15, 2024 (Business Wire) -- Ophirex, Inc., a company focused on developing an oral treatment for snakebite victims, has appointed Jeremy Gowler as CEO. Prior to joining Ophire
Burlington, MA, July 17, 2024 (Finance Yahoo) -- Cardurion Pharmaceuticals has raised a Series B Financing round of $260 million. The funding will expand the indications being considered for CRD-750
